Synthetic neuroactive tripeptide / EDR peptide
Pinealon is a three-amino-acid peptide researched for memory, brain-injury recovery, oxidative stress, and neuronal aging. Small human reports exist, but they are not modern Pinealon-only randomized trials; the clearest direct evidence is still from cells and animals.
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Research at a glance
Depth and confidence summarize the research record—not effectiveness, safety, or a recommendation.
Two small human reports are supplemented by cell and animal work, but no modern Pinealon-only randomized development program was located.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
The human reports cannot isolate a durable Pinealon effect, while the more detailed evidence remains preclinical.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not a suggested amount.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The underlying modern trial report was not located, and the observation does not establish causality, a reliable effect size, product equivalence, or a personal-use protocol. Amounts shown describe cited research exposure—not a dosage recommendation.
Practical starting point
Common goals and questions—not recommendations or promises of benefit.
The overview, studies, and source ledger below explain what supports each label—and where the evidence stops.
The short version
Pinealon is a three-amino-acid peptide researched for memory, brain-injury recovery, oxidative stress, and neuronal aging. Small human reports exist, but they are not modern Pinealon-only randomized trials; the clearest direct evidence is still from cells and animals.
Evidence reviewed through July 25, 2026. Pinealon/EDR is kept separate from Cortexin, Epithalon/AEDG, and other peptide bioregulators, and review-cited human observations are distinguished from directly traceable trials.
What the evidence says
A 32-person mixed Pinealon/Vesugen report plus a narrative review's account of a 72-person oral add-on observation; neither is a robust Pinealon-only randomized trial
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether any reported cognitive or cellular signal translates into clinically meaningful benefit and what short- and long-term human safety looks like
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
The evidence story
Importance shows how much an item changes the evidence story. Quality shows how much confidence the design deserves. A strong negative study can score highly on both.
Importance and quality answer different questions. A rigorous study can be highly important even when it challenges a popular claim.
EDR increased dendritic branching measures. It did not change mitochondrial activity, lysosomal activity, or p16, and the oxidative-DNA-damage result narrowly missed the conventional statistical threshold.
The review reports improvements in memory, headaches, performance measures, correction-test errors, and EEG alpha index after oral Pinealon was added to usual therapy.
The corrected paper reported more mushroom-shaped dendritic spines with EDR in the amyloid cell model.
The authors reported CNS and biological-age-marker changes with the peptide interventions, while Vesugen appeared more active. They also reported prooxidant activity and lower CD34-positive-cell markers.
Offspring in the Pinealon condition performed better on spatial-learning measures and showed lower neuronal ROS and necrotic-cell signals.
Administration and handling
Older reports describe oral Pinealon exposure, including add-on use after traumatic brain injury, but accessible peer-reviewed sources do not establish a regulator-approved dose, schedule, duration, or clinical protocol. Cell concentrations and animal injection schedules belong only to those experiments. No controlled human injectable Pinealon trial was located, so laboratory and animal exposure must not be converted into self-use instructions.
No FDA-approved Pinealon product label, validated consumer reconstitution procedure, sterile injectable specification, storage condition, beyond-use date, or compatibility standard was identified. Oral reports do not validate injectable products, and seller-labeled powders, salts, capsules, or solutions cannot be assumed equivalent, sterile, stable, or correctly identified.
Primary-source ledger
2024-10-22 · PMID 39518916 · DOI 10.3390/ijms252111363
2020-12-31 · PMID 33396470 · DOI 10.3390/molecules26010159
2017-08-29 · PMID 28853087 · DOI 10.1007/s10517-017-3847-2
2015-01-01 · PMID 26390612
2013-01-01 · PMID 24738258
2012-04-06 · PMID 22567179
2011-11-01 · PMID 22117547 · DOI 10.1134/S0006297911110022
2011-10-06 · PMID 21978084 · DOI 10.1089/rej.2011.1172